Compare Crispr Therapeutics AG (CRSP) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Gold Fields Limited — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Gold Fields Limited trades at $36.82 (market cap $31.87B). The key difference: Gold Fields Limited is far larger — about 6.5× Crispr Therapeutics AG's market cap, and Gold Fields Limited pays a 6% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Gold Fields Limited for 49 Days on average.
| CRSP | GFI | |
|---|---|---|
Market Cap | $4.88B | $31.87B |
Volume | 2,861,747 | 4,169,651 |
Sector | Health | Basic Materials |
52-Week High | $74.92 | $61.52 |
52-Week Low | $44.34 | $31.25 |
Typical Hold Time | 77 Days | 49 Days |
Enterprise Value | $3.30B | $32.47B |
Dividend Yield | — | 6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal but strong fundamentals. Revenue surged to $8.75B in 2025 with a net income margin of 38.66%, while valuation ratios like a P/E of 7.3 and EV/EBITDA of 4.64 suggest undervaluation. Recent news centers on a rejected $27B bid for Northern Star, causing volatility, but operational performance remains robust with record cash flow.
The outlook is mixed: analyst consensus is a Buy with a $52.75 price target, but technicals are bearish and earnings misses pose near-term risks. Upside hinges on execution of growth projects and gold price stability, while acquisition-related uncertainty and debt levels warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
